Gene: CACNA2D2

9254
CACNA2D
calcium voltage-gated channel auxiliary subunit alpha2delta 2
protein-coding
3p21.31
Ensembl:ENSG00000007402 MIM:607082 Vega:OTTHUMG00000156887 UniprotKB:Q9NY47
NG_034070.1
PubMed|SNP Mapped
2   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.225e-1 (AD)  7.385e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7612641chr3:50393047 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs7644782chr3:50387383 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CNNM10.912
L1CAM0.895
ARHGAP440.893
SEZ6L20.893
CLSTN30.891
SV2A0.889
ATP1A30.886
TACC20.885
SCN2B0.885
ADD20.884

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
YES1-0.541
REST-0.54
RAB13-0.539
WWTR1-0.536
RAI14-0.525
COPZ2-0.511
RNF135-0.504
TFPI2-0.5
WEE1-0.5
MYL3-0.498

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00270IsradipineSmall Molecule75695-93-1Approved|InvestigationalTarget
DB00996GabapentinSmall Molecule60142-96-3Approved|InvestigationalTarget
DB01023FelodipineSmall Molecule72509-76-3Approved|InvestigationalTarget
DB01054NitrendipineSmall Molecule39562-70-4Approved|InvestigationalTarget
DB01118AmiodaroneSmall Molecule1951-25-3Approved|InvestigationalTarget
DB01244BepridilSmall Molecule64706-54-3Approved|WithdrawnTarget
DB08872Gabapentin EnacarbilSmall Molecule478296-72-9Approved|InvestigationalTarget
DB00421SpironolactoneSmall Molecule52-01-7ApprovedTarget
ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of CACNA2D2 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNA2D2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNA2D2 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of CACNA2D2 mRNA17562736
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA25607892
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA25607892
C006632arsenic trioxidearsenic trioxide results in increased expression of CACNA2D2 mRNA15761015
D001194AsbestosAsbestos results in decreased expression of CACNA2D2 mRNA21563230
D001280AtrazineAtrazine results in increased expression of CACNA2D2 mRNA25929836
D001464BariumCACNA2D2 gene mutant form inhibits the reaction [CACNA1D protein results in increased import of Barium]27798183
D004958Estradiol[Estradiol binds to ESR2 protein] which results in increased expression of CACNA2D2 mRNA20404318
C006780bisphenol Abisphenol A results in decreased expression of CACNA2D2 mRNA25594700
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of CACNA2D2 mRNA25181051
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA25607892
D002118CalciumCACNA2D2 gene mutant form inhibits the reaction [CACNA1D protein results in increased import of Calcium]27798183
D002118CalciumCACNA2D2 protein affects the transport of Calcium14660671
D002118CalciumCACNA2D2 protein results in increased import of Calcium25504062
D002220CarbamazepineCarbamazepine affects the expression of CACNA2D2 mRNA25979313
D060729Coal AshCoal Ash results in increased expression of CACNA2D2 mRNA19000753
D016572CyclosporineCyclosporine results in decreased methylation of CACNA2D2 promoter27989131
D003630DaunorubicinDaunorubicin results in decreased expression of CACNA2D2 mRNA26537877|2894005
D003999Dichloroacetic AcidDichloroacetic Acid results in decreased expression of CACNA2D2 mRNA28962523
D004041Dietary FatsDietary Fats results in increased expression of CACNA2D2 mRNA25016146
D004317DoxorubicinDoxorubicin results in decreased expression of CACNA2D2 mRNA26537877|2894005
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA25607892
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of CACNA2D2 gene16724327
C040029gabapentingabapentin binds to CACNA2D2 protein11687876
C040029gabapentinCACNA2D2 protein affects the activity of gabapentin14660671
C040029gabapentingabapentin binds to CACNA2D2 protein14660671
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of CACNA2D2 mRNA"24972896
D008942MitoxantroneMitoxantrone results in decreased expression of CACNA2D2 mRNA26537877|2894005
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in increased expression of CACNA2D2 mRNA"29244179
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in increased expression of CACNA2D2 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D2 mRNA25607892
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNA2D2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of CACNA2D2 mRNA26272509
C005556propionaldehydepropionaldehyde results in increased expression of CACNA2D2 mRNA26079696
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of CACNA2D2 mRNA25895662
D019284ThapsigarginThapsigargin results in decreased expression of CACNA2D2 mRNA22378314
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in decreased expression of CACNA2D2 mRNA22363418
D014415TunicamycinTunicamycin results in decreased expression of CACNA2D2 mRNA22378314
D014635Valproic AcidValproic Acid results in increased methylation of CACNA2D2 gene29154799
D014639VanadiumVanadium results in increased expression of CACNA2D2 mRNA19000753

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005245voltage-gated calcium channel activity-TAS-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007528neuromuscular junction development-IEA-  
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0040014regulation of multicellular organism growth-IEA-  
GO:0046622positive regulation of organ growth-IEA-  
GO:0048747muscle fiber development-IEA-  
GO:0050796regulation of insulin secretion-TAS-  
GO:0060024rhythmic synaptic transmission-IEA-  
GO:0070588calcium ion transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005891voltage-gated calcium channel complex-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04260Cardiac muscle contraction
hsa05410Hypertrophic cardiomyopathy (HCM)
hsa05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)
hsa05414Dilated cardiomyopathy
Reactome ID Reactome Term Evidence
R-HSA-112308Presynaptic depolarization and calcium channel openingTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-1430728MetabolismTAS
R-HSA-1430728MetabolismIEA
R-HSA-163685Integration of energy metabolismTAS
R-HSA-163685Integration of energy metabolismIEA
R-HSA-397014Muscle contractionTAS
R-HSA-400042Adrenaline,noradrenaline inhibits insulin secretionIEA
R-HSA-422356Regulation of insulin secretionTAS
R-HSA-422356Regulation of insulin secretionIEA
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576892Phase 0 - rapid depolarisationTAS
R-HSA-5576893Phase 2 - plateau phaseTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28927526Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles. (2017 Jul)Cardoso MFSMutat Res